Crossmark

Cost Utility of Telaprevir–PR (Peginterferon–Ribavirin) Versus Boceprevir–PR and Versus PR Alone in Chronic Hepatitis C in The Netherlands

Published Online: 2014-08-08

Published Print: 2014-12

Authors

Vellopoulou, Aikaterini

van Agthoven, Michel

van der Kolk, Annemarie

de Knegt, Robert J.

Berdeaux, Gilles

Cure, Sandrine

Bianic, Florence

Lamotte, Mark
License Information

Text and Data Mining valid from 2014-08-08

Version of Record valid from 2014-08-08
More Information

Article History

First Online: 8 August 2014

Free to read: This content has been made available to all.

Document is current